Back to results
US 2024/0197671 A1Published application
Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims7
A method of treating a sleep disorder in an individual, the method comprising:
- instructing the individual that tasimelteon should not be administered with a beta-adrenergic receptor antagonist or a CYP1A2 inhibitor;
- and
- administering to the individual an effective amount of tasimelteon before bedtime,
- wherein the effective amount is an amount effective to advance the individual's melatonin circadian rhythm.
1 more element
Dependencies are inferred from the claim text.